Final answer:
Matrix metalloproteinases (MMPs), particularly MMP2 and MMP9, are often up-regulated in tumors and can be used as targets for drug delivery. Glomangioma tumors lacking specific enzymes were not identified, but angiogenesis inhibitors are a class of drugs used to prevent tumors from establishing a blood supply, which is necessary for their growth.
Step-by-step explanation:
The enzyme that glomangioma tumors lack has not been specifically mentioned in the context of the question. However, the question seems to relate to the concept of drugs that target tumors by taking advantage of enzymes they either lack or express in high amounts. In the case of other tumors, as mentioned in the reference materials, there is often an up-regulation of matrix metalloproteinases (MMPs), specifically MMP2 and MMP9, which play a role in tumor invasion, progression, and metastasis.
For cancer treatment, angiogenesis inhibitors are used because they can hinder the development of new blood vessels that tumors require to grow and spread. Without a sufficient blood supply, tumor growth is limited, potentially reducing the tumor size and the likelihood of metastasis. These drugs are a form of targeted therapy that aims to exploit the biological needs of malignant tumors for treatment advantage.